Mirae Asset Global Investments
YMAB

Mirae Asset Global Investments’s Y-mAbs Therapeutics YMAB Stock Holding History

Mirae Asset Global Investments’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,750
Closed -$7.89K – 1707
2025
Q2 		$7.89K Buy
1,750
+245
+16% +$1.1K ﹤0.01% 1516
2025
Q1 		$7.24K Buy
1,505
+12
+0.8% +$70 ﹤0.01% 1495
2024
Q4 		$11.9K Sell
1,493
-119
-7% -$1.45K ﹤0.01% 1493
2024
Q3 		$20.9K Buy
1,612
+302
+23% +$3.83K ﹤0.01% 1429
2024
Q2 		$16.2K Buy
+1,310
New +$17.7K ﹤0.01% 1409
2024
Q1 		– Sell
-26,090
Closed -$178K – 2669
2023
Q4 		$178K Buy
26,090
+1,089
+4% +$6.3K ﹤0.01% 2359
2023
Q3 		$136K Hold
25,001
– – ﹤0.01% 2394
2023
Q2 		$170K Buy
+25,001
New +$187K ﹤0.01% 2390
2023
Q1 		– Sell
-17,930
Closed -$87.5K – 2585
2022
Q4 		$87.5K Buy
17,930
+2,008
+13% +$14.6K ﹤0.01% 2469
2022
Q3 		$230K Buy
15,922
+4,736
+42% +$78.4K ﹤0.01% 2282
2022
Q2 		$169K Buy
+11,186
New +$131K ﹤0.01% 2193

Other funds holding YMAB

BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Mirae Asset Global Investments's YMAB Position: Q3 2025 in Review

Mirae Asset Global Investments sold out of Y-mAbs Therapeutics (YMAB) in Q3 2025, closing a stake of 1,750 shares — an estimated $7.89K sold.

Mirae Asset Global Investments first reported a position in YMAB in Q2 2022 and held it in 11 quarters. The position peaked at $230K in Q3 2022. 2 funds tracked by Wall St. Rank hold YMAB as of Q3 2025.

  • Mirae Asset Global Investments reported no remaining Y-mAbs Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Mirae Asset Global Investments sold 1,750 Y-mAbs Therapeutics shares in Q3 2025, an estimated $7.89K.
  • Mirae Asset Global Investments first reported a position in Y-mAbs Therapeutics in Q2 2022 and held it in 11 quarters.
  • Mirae Asset Global Investments's Y-mAbs Therapeutics position peaked at $230K in Q3 2022.
  • 2 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2025.

Based on Mirae Asset Global Investments's 13F filing for Q3 2025, filed 3 Nov 2025.